• Osteoporosis is a condition affecting, in a large part, post menopausal women. Women with this disease exhibit decreased bone mass and, hence, a significant increase in risk for bone fractures. Actonel is a drug that was developed to counteract the effects for osteoporosis. During the clinical trial phase for this drug 1,374 postmenopausal women were randomly divided into two groups. The experimental group were given Actonel while the women in the control group were treated" with a placebo. The response variable is whether or not a woman experiences a bone fracture anytime during the 1-yr trial phase". Of the 696 women in the experimental group, 27 suffered a bone fracture. In the control group, 49 of these women experienced a bone fracture.

  (a) The 90% CI for the proportion of women taking Actonel who suffered a bone fracture is (0.0268, 0.0508). From the choices below, the best interpretation of this interval is:

  i)90% of all samples of size n=696 will yield an estimated proportion between 0.0268 and 0.0508

  ii)We are confident that 90% of all samples of any size will yield an estimated proportion between 0.0268 and 0.0508.

  iii)We are 90% confident that the sample proportion will be between 0.0268 and 0.0508.

  iv) We are 90% confident that the sample proportion of women in the Actonel group who suffered a bone fracture is .0388.

  v) If the sampling procedure were repeated many times and a 90% confidence interval calculated from the observations in each sample, 90% of the resulting confidence intervals would contain the true proportion of women in the Actonel group who suffered a bone fracture; (0.0268, 0.0508) is one such interval.

  (b) What is the 90% CI for the proportion of women in the control group?

  (i) (0.03597, 0.05857)

  (ii) (0.05597, 0.08857)

  (iii) (0.01597, 0.03857)

  (iv) (0.07597, 0.09857)

  (v) (0.04597, 0.08857)